PREGNANCY: No evidence of fetal harm has been reported from use of piperacillin/tazobactam, piperacillin alone, and tazobactam alone in mice and rats (animal studies). Piperacillin/tazobactam is known to cross the placenta. Piperacillin/tazobactam is approved for the treatment of postpartum infections. As with all medications, piperacillin/tazobactam should be used cautiously in pregnancy. Potential benefits of treatment should be weighed against any potential risk to the fetus. Piperacillin and tazobactam is classified as FDA pregnancy risk category C.
NURSING MOTHERS: Piperacillin is excreted into human milk in small amounts. Excretion of tazobactam in human milk has not been studied. Due to the lack of safety data, piperacillin/tazobactam should be used cautiously in females who are breastfeeding.
REFERENCE: FDA Prescribing information.
Quick GuideSymptoms of Mono: Infectious Mononucleosis Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.